POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
PNT2004 program’s phase 1 FRONTIER trial design to be presented. Abstract to be released at 5:00 PM ET, May 25th. Poster to be available starting at 9:00 AM ET, June 3rd.
POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
U.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April 2023. Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer, Ionetix Alpha Corp.
POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp.
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
“The FDA Fast Track designation for 177Lu-PNT2002 underscores its potential to address a serious unmet need and serve as a meaningful therapeutic option for patients with mCRPC,” said Dr. Neil Fleshner, M.D., Chief Medical Officer of POINT Biopharma.
Eckert & Ziegler to Supply POINT Biopharma with Actinium-225
Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands.
POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates. Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023.
POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues or delays.
POINT Biopharma to Participate in Upcoming Investor Conferences
POINT today announced management will participate in the following upcoming investor conferences